by Wang, X., Song, X., Li, Y., Ding, Y., Yin, C., Ren, T., Zhang, W.
Background
T-cell receptor (TCR)-T immunotherapy has emerged as a promising strategy for cancer treatment. However, identifying TCRs that can be used to generate TCR-T cells remains challenging due to tumor heterogeneity, the scarcity of tumor-specifi…
Background
The hyporesponsiveness of tumor-infiltrating exhausted CD8+ T cells to tumor cells contributes to immune escape of renal cell carcinoma (RCC), representing a major challenge in current immunotherapy. However, the underlying molecular mechan…
by Zhang, P., Zhang, M., Liu, J., Zhou, Z., Zhang, L., Luo, P., Zhang, Z.
Background
Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer. Although immune checkpoint inhibitors (ICIs) have brought new treatment options for advanced patients, a considerable proportion still shows limited respon…
Background
A chemoimmunotherapy regimen consisting of a novel Wilms’ tumor 1 (WT1) peptide-pulsed dendritic cell (WT1-DC) vaccine and multiagent chemotherapy was observed to modulate the tumor microenvironment (TME) to an immunostimulatory state…
by Song, L., Qi, G., Shi, W., Zeng, Q., Qin, Y., Wang, Z., Li, W., Song, Z., Zhang, A., Lu, H.
Background
Immunocytokines targeting immune checkpoints have shown great potential in overcoming resistance to immune checkpoint blockade (ICB), making them a major focus of development in recent years. However, severe dose-limiting toxicity hindered …
